Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS and the SEA countries

2022年07月28日 16:17:46 来自: (0)参与

SINGAPORE -- (BUSINESS WIRE) --

Prestige Biopharma Limited (KRX: 950210, hereafter referred to as “Prestige”) and Intas Pharmaceuticals Limited (hereafter referred to as “Intas”) today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige Biopharma’s bevacizumab biosimilar, in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan and Tajikistan.

Prestige’s bevacizumab (HD204) is a mAb biosimilar to Roche’s Avastin®, an inhibitor of vascular endothelial growth factor (VEGF), which is used in combination with other therapies to treat patients with multiple forms of cancer including metastatic colorectal cancer, advanced non-small-cell lung cancer, advanced kidney cancer, certain types of epithelial cancers and cancers of the cervix. HD204 is currently in Phase III clinical development (SAMSON-II) and the US and EU filing is planned next year. Positive results were previously reported from the Phase I clinical trial (SAMSON-I) which evaluated the pharmacokinetics, safety and immunogenicity of HD204 to Avastin®.

The partnership arrangement includes the exclusive rights for Intas and its affiliate Accord Healthcare that will commercialize the bevacizumab biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan and Tajikistan, leveraging their strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market. As one of the key players in the global biosimilar market, Accord has a longstanding commitment to oncology with proven commercial capabilities and it currently supplies around one in three injectable oncology medicines in Europe.

This collaboration represents the successful execution of the company’s strategy to expand its market reach in Europe and Canada leveraging Accord’s strong global footprint and deep commercial expertise. The global sales of bevacizumab including its biosimilars were recorded at USD 6.4 billion1) last year and the market is expected to continue growing. Prestige’s HD204 with excellent cost competitiveness based on the company’s proprietary bevacizumab production technology will be providing affordable access to more patients in need.

Lisa S. Park, CEO of Prestige Biopharma, commented: “We are delighted to establish a partnership with Intas for the key markets, the US and Europe. Accord is the ideal partner to commercialize our bevacizumab biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.”

Binish Chudgar, Vice Chairman & Managing Director of Intas Pharmaceuticals, commented: “We are pleased to announce the collaboration with Prestige Biopharma. This collaboration is in line with our long-term strategy and reinforces our commitment to improving access to high-quality biosimilar drugs for cancer patients globally.”

About Prestige Biopharma Limited:  
Prestige Biopharma Ltd. is a Singapore-based biopharmaceutical company with operations in USA and Korea, specialising in the discovery and development of biosimilars, novel antibodies and vaccines. The company strives to become a global innovator through the development of first-in-class mAbs including PBP1510 (INN: Ulenistamab) anti-PAUF mAb for pancreatic cancer that recently obtained FDA approval for Phase 1/2a IND and orphan designation from FDA, EMA and MFDS. Prestige's rich portfolio of biosimilars in various stages including HD201 trastuzumab under marketing authorisation review, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. Prestige’s business also includes alliance vaccine development and production, starting with the partnered commercial production of COVID-19 vaccines. For more information, please visit www.prestigebiopharma.com.

About Intas Pharmaceuticals Limited:  
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. The organisation has more than 18,000 employees and 14 manufacturing sites worldwide and sells products in more than 85 countries. The Intas Group's revenue amounted to USD 2.3 bn in FY 2020-21 and the compounded annual growth rate of revenue has been 19% in the past 5 years. For more information, please visit www.intaspharma.com.

1) Source: IQVIA  

View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005480/en/

CONTACT:

Media inquiries:  
Global Communication Team  
Prestige Biopharma Ltd.  
www.prestigebiopharma.com  
Tel: +65-6924-6535  
info@prestigebio.com

相关新闻
本网网友:言简而悲伤∝
评论:装傻这事,如果干的好,叫大智若愚

淘宝网友:往日 °Cold
评论:放屁的时候你有木有想过内裤的感受

天涯网友:光棍节的忧伤
评论:如果有人和你说:不要脸。你可以对他说:对你根本不需要有脸!

百度网友:时光° Moon
评论:好的爱情,战得胜时间,抵得住流年,经得起离别,受得住想念。

腾讯网友:我依舊依賴你
评论:我是一个很有原则的人,我的原则只有三个字,看心情

搜狐网友:渲染那份寂寞
评论:再过五十年我就是古董了,所以你趁现在赶紧好好收藏我吧

凤凰网友:没你爸风骚 -
评论:真正的爱情,不是一见钟情,而是日久生情 人人都说我很听话,其实我只听自己的话。

网易网友:柔眸1  Demon
评论:向上爬时,对遇到的人好点,因为掉下来时,你还会遇到他们。

天猫网友:听ヽ天甾哭泣
评论:一切不以睡眠为目的的度周末,都是耍流氓!

猫扑网友:哥只是寂寞
评论:坐地铁,是一项糅合太极,柔道,缩骨功的综合性运动。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin